Hodgkin’s lymphoma (HL) is a clonal malignancy of the lymphatic system that arises from B cells of germinal and post-germinal centers. The disease has a bimodal age distribution, the first is observed between 15 and 30 years old and the second in the over 55 years old age group. Broadly, it is classified into classical and nodular lymphocyte-predominant HL. Classical HL is further subclassified into nodular sclerosis, lymphocyte rich, lymphocyte depleted, and mixed cellularity. PET plays an important role in staging and response assessment. Both chemotherapy and Radiotherapy plays an important role in the management of Pediatric HL. Also, challenges in managing these patients in the Low and Middle income countries (LMIC ) still exits.